The findings of our study reveal the potential pharmacological mechanism through which cGAMP can reverse OXA resistance in colorectal cancer and increase p53 expression by inhibiting the PI3K/AKT signaling axis, thereby promoting tumor cell apoptosis and enhancing the anti-tumor immune response. Here, TP53 is linked to colorectal cancer.